The group has identified a number of proteins that are, in part, associated with resistant chemotherapy. It has developed inhibitors to this resistance that sensitize patients to the effects of chemotherapy and is currently developing therapeutic strategies for clinical trials early next year. Dr. Maxwell’s group is also finalizing a phase 1b study using a vaccine therapy for patients with ovarian and endometrial cancer.
“We’re doing lots of science that’s important, ultimately contributing to our overall knowledge of gynecologic cancers,” Dr. Maxwell says.
# # #
Heather Perez Saiz, MA, LCSW, CCTSW, is the Independent Living Donor Advocate at Inova Fairfax…
Palak Shah, MD, MS Fairfax, VA — A research team at Inova Schar Heart and…
Jason Bonomo, MD, PhD, is a cardiologist at Inova Schar Heart and Vascular. Dr. Bonomo…
Update as of April 24, 2024: Inova’s structural heart team has now completed the first…
The Peterson Family Fairfax, VA, April 16, 2024 – Inova today announced a transformational gift…
Lauren Trahan, MS, RD is a Registered Dietitian. She serves patients in Inova Cardiac and…